107 related articles for article (PubMed ID: 25067805)
1. Reinforcement of the intestinal mucus layer protects against Clostridium difficile intestinal injury in vitro.
Diebel LN; Liberati DM
J Am Coll Surg; 2014 Sep; 219(3):460-8. PubMed ID: 25067805
[TBL] [Abstract][Full Text] [Related]
2. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin.
Olson A; Diebel LN; Liberati DM
J Trauma Acute Care Surg; 2014 Oct; 77(4):570-5; discussion 576. PubMed ID: 25250596
[TBL] [Abstract][Full Text] [Related]
3. Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury.
Olson A; Diebel LN; Liberati DM
J Trauma Acute Care Surg; 2013 Apr; 74(4):983-89; discussion 989-90. PubMed ID: 23511135
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylcholine and the intestinal mucus layer: in vitro efficacy against Clostridium difficile-associated polymorphonuclear neutrophil activation.
Olson A; Diebel LN; Liberati DM
Am J Surg; 2015 Mar; 209(3):493-7. PubMed ID: 25595713
[TBL] [Abstract][Full Text] [Related]
5. Discussion.
J Am Coll Surg; 2014 Sep; 219(3):468-9. PubMed ID: 25151342
[No Abstract] [Full Text] [Related]
6. Estrogen modulates intestinal mucus physiochemical properties and protects against oxidant injury.
Diebel ME; Diebel LN; Manke CW; Liberati DM
J Trauma Acute Care Surg; 2015 Jan; 78(1):94-9. PubMed ID: 25539208
[TBL] [Abstract][Full Text] [Related]
7. Early tranexamic acid administration: A protective effect on gut barrier function following ischemia/reperfusion injury.
Diebel ME; Diebel LN; Manke CW; Liberati DM; Whittaker JR
J Trauma Acute Care Surg; 2015 Dec; 79(6):1015-22. PubMed ID: 26317817
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture.
Eveillard M; Fourel V; Barc MC; Kernéis S; Coconnier MH; Karjalainen T; Bourlioux P; Servin AL
Mol Microbiol; 1993 Feb; 7(3):371-81. PubMed ID: 8459765
[TBL] [Abstract][Full Text] [Related]
9. Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29.
Valdés L; Gueimonde M; Ruas-Madiedo P
J Microbiol Methods; 2015 Dec; 119():66-73. PubMed ID: 26436983
[TBL] [Abstract][Full Text] [Related]
10. New trends in Clostridium difficile virulence and pathogenesis.
Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
[TBL] [Abstract][Full Text] [Related]
11. Mucosal protection by phosphatidylcholine.
Stremmel W; Ehehalt R; Staffer S; Stoffels S; Mohr A; Karner M; Braun A
Dig Dis; 2012; 30 Suppl 3():85-91. PubMed ID: 23295697
[TBL] [Abstract][Full Text] [Related]
12. Gender dimorphism in the gut: mucosal protection by estrogen stimulation of IgA transcytosis.
Diebel ME; Diebel LN; Liberati DM
J Trauma; 2011 Aug; 71(2):474-9. PubMed ID: 21825949
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of varying concentrations of clostridium difficile toxin A on epithelial barrier function and expression of cytokines.
Johal SS; Solomon K; Dodson S; Borriello SP; Mahida YR
J Infect Dis; 2004 Jun; 189(11):2110-9. PubMed ID: 15143480
[TBL] [Abstract][Full Text] [Related]
14. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization.
Tasteyre A; Barc MC; Collignon A; Boureau H; Karjalainen T
Infect Immun; 2001 Dec; 69(12):7937-40. PubMed ID: 11705981
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile toxins and enterococcal translocation in vivo and in vitro.
Feltis BA; Garni RM; Wells CL
J Surg Res; 2001 May; 97(1):97-102. PubMed ID: 11319888
[TBL] [Abstract][Full Text] [Related]
16. H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro.
Diebel LN; Liberati DM; Hall-Zimmerman L
Surgery; 2011 Oct; 150(4):736-43. PubMed ID: 22000186
[TBL] [Abstract][Full Text] [Related]
17. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases.
Vaishnavi C
Indian J Med Res; 2010 Apr; 131():487-99. PubMed ID: 20424299
[TBL] [Abstract][Full Text] [Related]
18. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
20. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
